Cascadia Advisory Services’s ARK Genomic Revolution ETF ARKG Stock Holding History

Cascadia Advisory Services’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$814K	Sell	10,892 -1,533	-12%	-$129K	0.17%	135
2021 Q2	$1.15M	Sell	12,425 -9,406	-43%	-$800K	0.25%	110
2021 Q1	$1.94M	Buy	+21,831	New	+$2.17M	0.43%	85
2020 Q3	$719K	Buy	+11,292	New	+$662K	0.2%	135

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Cascadia Advisory Services's ARKG Position: Q3 2021 in Review

Cascadia Advisory Services reduced its ARK Genomic Revolution ETF (ARKG) stake by 12% in Q3 2021, selling an estimated $129K and leaving 10,892 shares worth $814K. The position accounts for 0.17% of the portfolio, ranked #135.

Cascadia Advisory Services first reported a position in ARKG in Q3 2020 and has held it in 4 quarters since. The position peaked at $1.94M in Q1 2021. 469 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

Cascadia Advisory Services held 10,892 shares of ARK Genomic Revolution ETF worth $814K as of Q3 2021.
Cascadia Advisory Services sold 1,533 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $129K.
ARK Genomic Revolution ETF made up 0.17% of Cascadia Advisory Services's portfolio in Q3 2021, its #135 holding.
Cascadia Advisory Services first reported a position in ARK Genomic Revolution ETF in Q3 2020 and has held it in 4 quarters since.
Cascadia Advisory Services's ARK Genomic Revolution ETF position peaked at $1.94M in Q1 2021.
469 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on Cascadia Advisory Services's 13F filing for Q3 2021, filed 12 Nov 2021.